Group 1 - The company announced a change in control agreement where Qin Benjun will transfer 60 million shares (8.09%) to Guangzhou Defu Nutrition and relinquish voting rights for 189,141,310 shares (25.50%), retaining voting rights for 22,248,282 shares (3.00%) [1] - Following the completion of the share transfer and board restructuring, Guangzhou Defu Nutrition will become the controlling shareholder, with Hou Ming and Li Zhenfu as the joint actual controllers of the company [1] - The company plans to acquire 80% of Beijing Jinkangpu Food Technology Co., Ltd. through a share issuance to Defu Jinkangpu Holdings and Xiamen Defu Jinkangpu Investment [1] Group 2 - The target company specializes in the formulation, production, testing, sales, and technical services of food nutrition fortifiers, serving various sectors including dairy products and functional beverages [2] - The target company is a leading enterprise in the food nutrition fortifier industry, supplying to numerous infant formula manufacturers [2] - The acquisition will enhance the company's business structure, making it more diversified and improving operational stability and risk resistance [2] Group 3 - The company's stock will resume trading on December 24, 2025 [3]

（文章来源：证券日报） 证券日报网讯 12月23日，莱茵生物发布公告称，公司第七届董事会第十次会议审议通过《关于公司符 合发行股份购买资产并募集配套资金暨关联交易条件的议案》等多项议案。 ...

Core Viewpoint - The company is undergoing a significant change in control and is expanding its business into the food nutrition fortifier sector through the acquisition of Beijing Jinkangpu Food Technology Co., Ltd. Group 1: Control Change - The company's controlling shareholder, Qin Benjun, has signed agreements to transfer 60 million shares (8.09% of total shares) to Guangzhou Defu Nutrition and will relinquish voting rights for 189 million shares (25.50% of total shares), retaining voting rights for 22.2483 million shares (3.00% of total shares) [1] - Following the completion of the share transfer and board restructuring, Guangzhou Defu Nutrition will become the controlling shareholder, with Hou Ming and LIZHENFU as the joint actual controllers [1] Group 2: Acquisition Details - The company has signed agreements to issue shares to acquire 80% of Beijing Jinkangpu, while also raising funds through share issuance to purchase an additional 15.50% stake from individual shareholders [1] - Beijing Jinkangpu specializes in the formulation, production, and sales of food nutrition fortifiers, serving as a leading supplier for infant formula manufacturers in China [2] Group 3: Strategic Benefits - The acquisition will allow the company to expand its business into the food nutrition fortifier sector, creating a closed-loop industry chain from raw materials to formulation solutions [2] - The partnership with Beijing Jinkangpu is expected to enhance the company's product coverage in the dairy sector and facilitate international expansion through its global sales network [2] - Post-transaction, Beijing Jinkangpu's financials will be consolidated into the company's reports, improving asset scale, revenue, and net profit, thereby diversifying income sources and enhancing operational stability [3]

Group 1 - The controlling shareholder of the company, Qin Benjun, plans to transfer 60 million shares (8.09% of total share capital) to Guangzhou Defu Nutrition and will relinquish voting rights for 189,141,310 shares (25.50% of total share capital), retaining 3.00% voting rights [1] - Guangzhou Defu Nutrition will become the controlling shareholder of the company, with Hou Ming and Li Zhenfu as the joint actual controllers [1] - The company intends to acquire 80% of Beijing Jinkangpu Food Technology Co., Ltd. through a share issuance and raise additional funds for purchasing 15.50% equity from natural shareholders Li Yang and Song Jun, as well as covering intermediary fees, transaction taxes, and supplementing working capital [1] Group 2 - The target company specializes in the formulation, production, testing, sales, technological innovation, and services of food nutrition fortifiers, widely used in dairy products, functional beverages, complementary foods, medical foods, and health foods [2] - The target company is a leading enterprise in the food nutrition fortifier sector, supplying nutrition fortifiers to numerous infant formula manufacturers both domestically and internationally [2] - The acquisition will allow the listed company to expand its industrial chain into the nutrition fortifier compounding field, creating a closed-loop from upstream raw materials to downstream formulation solutions, enhancing business synergy and stability [2]

Group 1 - The core point of the article is that Rhine Biology (002166.SZ) is undergoing significant changes in its ownership structure and is planning to acquire a majority stake in Beijing Jinkangpu Food Technology Co., Ltd. [1] - The controlling shareholder, Qin Benjun, intends to transfer 60 million shares (8.09% of total share capital) to Guangzhou Defu Nutrition and will relinquish voting rights for 189,141,310 shares (25.50% of total share capital), retaining only 3.00% voting rights [1] - Following this transfer, Guangzhou Defu Nutrition will become the controlling shareholder, with Hou Ming and Li Zhenfu as the joint actual controllers of the company [1] Group 2 - The target company specializes in the formulation, production, testing, sales, technological innovation, and services of food nutrition fortifiers, which are widely used in dairy products, functional beverages, complementary foods, medical foods, and health foods [2] - The target company is a leading enterprise in the food nutrition fortifier sector, supplying nutrition fortifiers to numerous infant formula manufacturers both domestically and internationally [2] - This acquisition will allow the listed company to expand its industrial chain into the nutrition fortifier compounding field, creating a closed-loop from upstream raw materials to downstream formulation solutions, enhancing business synergy and stability [2]

此外，莱茵生物拟通过发行股份的方式向德福金康普控股有限合伙企业和厦门德福金普投资合伙企业 （有限合伙）购买其合计持有的北京金康普食品科技有限公司（以下简称"北京金康普"）80%股权。同 时拟向广州德福营养发行股份募集配套资金，用于购买北京金康普股东李洋、宋军15.5%股权、支付中 介费用、交易税费和补充流动资金。 北京商报讯（记者 马换换 李佳雪）12月23日晚间，莱茵生物（002166）披露公告称，广州德福营养投 资合伙企业（有限合伙）（以下简称"广州德福营养"）将成为公司控股股东，侯明和LIZHENFU将成为 公司共同实际控制人。公司股票将于12月24日起复牌。 公告显示，广州德福营养与莱茵生物控股股东、实际控制人秦本军签订《控制权变更框架协议》《股份 转让协议》和《表决权放弃协议》，约定秦本军向广州德福营养协议转让其所持有的公司6000万股股份 （比例为8.09%），放弃1.89亿股股份表决权（比例为25.5%），保留2224.83万股股份表决权（比例为 3%）。 ...

Core Viewpoint - The company, Rhein Biotech, plans to acquire an 80% stake in Beijing Jinkangpu Food Technology Co., Ltd., a leading provider of nutritional fortifiers for infant formula, thereby expanding its industry chain into the nutritional fortifier compounding sector [1] Group 1: Acquisition Details - Rhein Biotech intends to issue shares to Defu Jinkangpu and Xiamen Defu Jinkangpu to purchase their combined 80% stake in Beijing Jinkangpu [1] - The transaction is still pending completion of auditing and evaluation work [1] Group 2: Strategic Implications - The acquisition will create a closed-loop industry chain from upstream raw materials to downstream formulation solutions in the nutritional fortifier sector [1] Group 3: Shareholder Changes - On December 22, Guangzhou Defu Nutrition signed an agreement with the company's original controlling shareholder, Qin Benjun, to transfer 8.09% of shares and relinquish voting rights for 25.5% of shares, retaining voting rights for 3% [1] - Following the share transfer and board restructuring, Guangzhou Defu Nutrition will become the controlling shareholder, with Hou Ming and Li Zhenfu as co-controlling persons [1] - Guangzhou Defu Nutrition, Defu Jinkangpu, and Xiamen Defu Jinkangpu are related entities under common control [1] Group 4: Stock Resumption - The company's stock will resume trading on December 24 [1]

2025年1至6月份，莱茵生物的营业收入构成为：制造业占比98.71%，其他行业占比1.29%。 （记者 曾健辉） 截至发稿，莱茵生物市值为65亿元。 每经AI快讯，莱茵生物（SZ 002166，收盘价：8.7元）12月23日晚间发布公告称，公司第七届第十次董 事会会议于2025年12月22日在公司四楼会议室以现场方式召开。会议审议了《关于本次交易相关议案暂 不提交股东会审议的议案》等文件。 每经头条（nbdtoutiao）——地产"优等生"受困20亿元到期债务，首次债务展期仍在博弈，明年还有超 百亿元公开债到期 ...

桂林莱茵生物科技股份有限公司 详式权益变动报告书 桂林莱茵生物科技股份有限公司 详式权益变动报告书 上市公司名称：桂林莱茵生物科技股份有限公司 股票上市地点：深圳证券交易所 股票简称：莱茵生物 股票代码：002166 权益变动性质：股份增加（协议转让、转让方表决权放弃） 签署日期：二〇二五年十二月 桂林莱茵生物科技股份有限公司 详式权益变动报告书 信息披露义务人声明 一、本报告书系依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》《公开发行证券的公司信息披露内容与格式准则第 16 号——上市公司收购报告书》等相关法律、法规和规范性文件编制。 二、依据《中华人民共和国证券法》《上市公司收购管理办法》的规定， 本报告书已全面披露了信息披露义务人在桂林莱茵生物科技股份有限公司中拥 有权益的股份。截至本报告书签署之日，除本报告书披露的信息外，信息披露 义务人没有通过任何其他方式在桂林莱茵生物科技股份有限公司拥有权益。 三、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不 违反其章程或内部规则中的任何条款， ...

桂林莱茵生物科技股份有限公司 签署日期：二〇二五年十二月 信息披露义务人声明 简式权益变动报告书 上市公司名称：桂林莱茵生物科技股份有限公司 股票上市地点：深圳证券交易所 股票简称：莱茵生物 股票代码：002166 信息披露义务人：秦本军 住所：广西壮族自治区桂林市七星区穿山东路 通讯地址：广西壮族自治区桂林市七星区穿山东路 权益变动性质：股份减少（协议转让、表决权放弃） 一、本报告书系依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》等相关法律、法规和规范性文件编制。 二、依据《中华人民共和国证券法》《上市公司收购管理办法》的规定， 本报告书已全面披露了信息披露义务人在桂林莱茵生物科技股份有限公司中拥 有权益的股份。截至本报告书签署之日，除本报告书披露的信息外，信息披露 义务人没有通过任何其他方式在桂林莱茵生物科技股份有限公司拥有权益。 三、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不 违反其章程或内部规则中的任何条款，或与之相冲突。 四、本次权益变动尚需履行如下程序：1、本次交易中受让股权 ...